Clinical Trial Update: Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism [Phase 3]

View source ↗

Summary

Phase 3 study of KHK7580 for hypercalcemia in parathyroid carcinoma or primary hyperparathyroidism completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism
• Parathyroid Carcinoma

Drugs mentioned

• KHK7580

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Parathyroid Carcinoma, Primary Hyperparathyroidism | Phase 3 | Status: COMPLETED | Results posted: 2021-05-27